How Mounjaro Stacks Up Against Wegovy for Type 2 Diabetes
Mounjaro (tirzepatide) outperforms Wegovy (semaglutide) in blood sugar control and weight loss for type 2 diabetes patients, based on head-to-head trials. In the SURPASS-2 study, Mounjaro reduced A1C by 2.3% at the highest dose (15 mg) versus 1.9% for Wegovy (1 mg), with greater weight loss: 12 kg versus 7 kg over 40 weeks.[1] Both drugs belong to the GLP-1 agonist class, but Mounjaro also activates GIP receptors, enhancing its effects on insulin secretion and appetite suppression.
Weight Loss Results in Diabetes Patients
For type 2 diabetes, Mounjaro delivers more substantial weight reduction. SURPASS-2 showed 15-22% body weight loss with Mounjaro (5-15 mg) compared to 11% with Wegovy (2.4 mg, though trial used 1 mg).[1] Real-world data from a 2023 study echoed this, with Mounjaro users losing 15.3% body weight at six months versus 10.9% for Wegovy users.[2] This edge stems from dual GIP/GLP-1 action, which curbs hunger more effectively.
A1C Reduction and Glycemic Control
Mounjaro lowers A1C more reliably. In trials like SURPASS-2, it achieved A1C below 7% in 82-86% of patients (higher doses) versus 68% on Wegovy.[1] SURPASS-1 to SURPASS-5 confirmed consistent superiority across doses and patient groups.[3] Wegovy, approved mainly for obesity, shows solid A1C drops (1.5-2%) in diabetes cohorts but lags behind Mounjaro's 2-2.5% reductions.
Side Effects and Safety Profile
Both cause similar gastrointestinal issues—nausea (12-18%), diarrhea (12-17%), vomiting (5-10%)—but Mounjaro's rates are slightly higher initially due to faster titration.[1][4] Serious risks like pancreatitis or thyroid tumors are rare for both, per FDA labels. Mounjaro has a black box warning for thyroid C-cell tumors (rodent data), matching Ozempic/Wegovy class effects. No head-to-head mortality data differs significantly.
Dosing Schedules and Administration
Mounjaro starts at 2.5 mg weekly, titrating to 15 mg; Wegovy at 0.25 mg to 2.4 mg weekly. Both are single-dose pens. Mounjaro offers more dose steps (7 vs. 5), allowing finer adjustments for tolerance. Injection sites and storage are comparable.
Cost and Insurance Coverage for Diabetes
Mounjaro lists at $1,069/month (15 mg), Wegovy at $1,349 (2.4 mg), before insurance.[5] For type 2 diabetes, Mounjaro (branded as Zepbound for weight loss) often gets better Medicare Part D coverage since FDA approval in 2022; Wegovy lacks diabetes indication, complicating reimbursement. Copays average $25-100/month with coverage for either.
Who Makes Them and Availability
Eli Lilly manufactures Mounjaro; Novo Nordisk makes Wegovy. Both face shortages, but Mounjaro ramped up U.S. supply in 2024. No generic versions exist; patents extend to 2035-2036.6
| Aspect | Mounjaro (Tirzepatide) | Wegovy (Semaglutide) |
|--------|-------------------------|-----------------------|
| Primary Mechanism | GLP-1 + GIP agonist | GLP-1 agonist |
| A1C Reduction (max dose) | 2.3-2.5% [1][3] | 1.9% [1] |
| Weight Loss (40-72 weeks) | 12-22 kg / 15-22% [1][2] | 7-15% [1][2] |
| FDA Approval for T2D | Yes (2022) | No (obesity only) |
| Weekly Dose Range | 2.5-15 mg | 0.25-2.4 mg |
| Common Side Effects | Nausea, diarrhea (higher initial rates) [4] | Nausea, diarrhea [4] |
Sources:
[1]: SURPASS-2 Trial (NEJM)
[2]: Real-world study (JAMA)
[3]: SURPASS Program Overview (Diabetes Care)
[4]: FDA Labels (Mounjaro), Wegovy
[5]: GoodRx Pricing (2024)